Anuradha Lala-Trindade
Cardiovascular Disease · New York, NYNPI 1003076902
Payments from drug & device makers
Across 418 payments — averaging $3657.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- American Regent$645K
- Novartis$297K
- Merck$201K
- Abiomed$58K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$57K
- AstraZeneca$43K
- plus $228K from 29 others
What the payments were for
- Consulting fees$140,26043%
- Speaking & faculty fees$133,83041%
- Grants$2,1211%
- Travel & lodging$37,14311%
- Food & beverage$11,0073%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| American Regent | 18 | $644,771 |
| Novartis | 19 | $297,360 |
| Merck | 52 | $201,330 |
| Abiomed | 32 | $57,650 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 38 | $56,576 |
| AstraZeneca | 26 | $42,888 |
| Novo Nordisk | 13 | $40,273 |
| Boehringer Ingelheim International GmbH | 25 | $32,167 |
| Novo Nordisk AS | 7 | $27,161 |
| Astrazeneca UK Limited | 5 | $24,654 |
| Lexicon Pharmaceuticals, Inc. | 9 | $21,540 |
| Procyrion, Inc. | 1 | $16,220 |
| Abbott | 103 | $15,940 |
| Bayer | 7 | $14,152 |
| Sanofi US Services Inc. | 3 | $9,580 |
| Impulse Dynamics (USA) Inc. | 3 | $5,032 |
| Nuwellis, Inc. | 1 | $5,000 |
| Boston Scientific | 7 | $3,746 |
| Idorsia Pharmaceuticals US Inc | 1 | $3,540 |
| Novo Nordisk Health Care AG | 1 | $3,140 |
| Organon | 1 | $2,500 |
| W. L. Gore & Associates, Inc. | 2 | $1,061 |
| ZOLL Circulation Inc | 2 | $1,045 |
| E.r. Squibb & Sons, L.L.C. | 12 | $282 |
| Boehringer Ingelheim | 11 | $238 |
| Vifor Pharma, Inc. | 2 | $223 |
| Cvrx, Inc. | 1 | $141 |
| Atricure, Inc. | 1 | $141 |
| Heartflow, Inc. | 4 | $86 |
| Philips North America LLC | 2 | $72 |
| Bridgebio Pharma, Inc. | 3 | $56 |
| Pfizer | 3 | $55 |
| Johnson & Johnson | 1 | $32 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$57,092
- LifeVest$56,365
- Kerendia$14,017
- Inpefa$11,250
- VERQUVO$11,036
- OPTIMIZER$10,000
- ENTRESTO$7,076
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$5,752
- Tryvio$3,540
- HeartMate 3 Left Ventricular Dev$3,021
- HeartMate 3 Left Ventricular Assist Device$2,987
- GENERAL - STRUCTURAL HEART$1,250
- GENERAL TACHY$1,222
- CARDIOMEMS$1,063
- Product in Development$1,061
- TherOx DS2 Console$1,045
- Catheter$1,045
- Downstream Cartridge$1,045
- BodyGuardian$899
- CardioMEMS HF System$894
How this compares
$1,528,694 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 63 | $50,715 |
| FarxigaDapagliflozin Propanediol | 46 | $35,633 |
| JardianceEmpagliflozin | 29 | $34,244 |
| EliquisApixaban | 37 | $29,216 |
| OzempicSemaglutide | 19 | $24,451 |
| Everolimus | 18 | $13,337 |
| Tacrolimus | 28 | $8,281 |
| Praluent PenAlirocumab | 11 | $6,134 |
| Mycophenolic AcidMycophenolate Sodium | 11 | $2,522 |
| Rosuvastatin Calcium | 65 | $762 |
| Hydralazine Hcl | 20 | $525 |
| Bumetanide | 11 | $518 |
| Metoprolol Succinate | 33 | $508 |
| Ezetimibe | 21 | $485 |
| Carvedilol | 36 | $334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $297,360 | $50,71563 claims |
| AstraZenecaFarxiga | $42,888 | $35,63346 claims |
| Boehringer IngelheimJardiance | $238 | $34,24429 claims |
| PfizerEliquis | $55 | $29,21637 claims |
| Novo NordiskOzempic | $40,273 | $24,45119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Gregg StoneNew York$3.7M
- Valentin FusterNew York$2.9M
- Tamim NazifNew York$2.2M
- Howard WeintraubNew York$1.7M
- Cezar StaniloaeNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.